XLO

Xilio TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

Current thesis

Composite grade D from latest DB weights. Momentum 29.2 / Value 56.8

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.2.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

— · Net —

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net —

Target $20.00

Why

Momentum29 · Δ7d -

Value57 · Δ7d -0.2

SentimentN/A · Δ7d -

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

60% active weight

Current posture

7d trendFlat

Δ7d

-0.2

Δ21d

-0.1

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade D. Momentum 29.2 / Value 56.8

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$58.39M

Beta

-0.04

Shares Out

6.58M

P/E (TTM) · Derived

-2.1

P/S (TTM)

1.12

P/FCF (TTM) · Derived

-1.64

Rev YoY

+331.7%

EPS YoY

-76.6%

Gross Margin

+97.4%

Op Margin

-137.6%

Net Debt

-$130.58M

Current Ratio

3.59

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology